drugset / Trial / NCT06393127
A Study in Healthy People to Compare How 2 Different High Dose Formulations of BI 1015550 Are Taken up in the Body
RandomizedCrossoverOpen-labelTreatment
Summary
The main objective of this trial is to establish the bioequivalence of the BI 1015550 Formulation C2 (Test, T) and the BI 1015550 Formulation C1 (Reference, R), following a single oral dose administration.
Timeline
- Start
- 2024-06-04
- Primary completion
- 2024-09-10
- Completion
- 2024-09-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nerandomilast | Small molecule | — | Oral |
Indications
No indication recorded.